EdithAdaljisaPerezMD

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Vice President and Head, U.S. BioOncology Medical Unit at Genentech, Inc.; Director, Breast Cancer Translational Genomics Program at Mayo Clinic; Member, Board of Directors of the American Association for Cancer Research

Join to view full profile

Dr. Perez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Perez's full profile

Already have an account?

Office
4500 San Pablo Rd S
Jacksonville, FL 32224
Phone+1 904-953-2000
Is this information wrong?

Education & Training

Martinez Veterans Affairs Medical CenterFellowship, Hematology and Medical Oncology, 1984 - 1987
Loma Linda University Health Education ConsortiumResidency, Internal Medicine, 1979 - 1982
University of Puerto Rico School of MedicineClass of 1979
University of Puerto RicoB.S., Biology, Magna Cum Laude, 1975

Certifications & Licensure

CA State Medical License 1980 - Present
FL State Medical License 1995 - 2026
MN State Medical License 1995 - 1996
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Expert - Breast Cancer Expertscape, 2014
Claude Jacquillat Award International Congress on Anticancer Treatment, 2014
Giants of Cancer Care Award OncLive, 2014
Clinical Medicine Highly Cited Researcher Thomson Reuters, 2014
America's Top Doctors Castle Connolly, 2006-2014
JU Community Woman of the Year, Womens History Month Committee Jacksonville University, 2013
Susan G. Komen - Brinker Award for Scientific Distinction in Clinical Research Susan G. Komen for the Cure, 2013
Woman of Vision Award The Girls Inc., FL, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
75 Most Influential People in Jacksonville Healthcare Jacksonville Magazine's 904: Northeast Florida's Business and Executive Life Authority, 2012
Hispanic Heritage Leadership Award NFL, 2011
Outstanding Course Director Mayo Clinic College of Medicine, 2010
Alpha Omega Alpha Alpha Omega Alpha Honor Medical Society, 2009
Women's Health Castle Connolly, 2008
Distinguished Investigator, Executive Board and Research Committee Mayo Clinic, 2007
Healthcare Heroes Super Scientist Jacksonville Business Journal, 2006
Honorary Doctorate of Letters University of North Florida, 2006
Serene M. and Frances C. Durling Professor of Medicine Mayo Clinic College of Medicine, Jacksonville, FL, 2006
Outstanding Faculty Member Mayo Clinic College of Medicine, 2004
Honorary Citizen and Day Proclamation City of Little Rock, AR, 2003
North Florida Hispanic of the Year Hispanics Achieving Community Excellence, 2003
Horizon Scientific Cancer Research Award Bristol Myers Squibb and Susan G. Komen Foundation, 2002
Outstanding Faculty Members Mayo Clinic College of Medicine, 2002, 2004, 2009
Crusader for Breast Cancer Award Rainbows Abound, Jacksonville, FL, 2001
Celebration of Leadership Award Community Connections, 2000
Sponsored Research Funding Award Office of Technology, Office of Intellectual Property (formerly Mayo Medical Ventures), 2000
Fellow American College of Physicians, 1998
Sigma Xi, The Scientific Research Society 1996
NCI Travel Award American Association for Cancer Research, 1987
Who's Who in American Women's Biography 1983
Scholarship National Health Service Corps, 1975
Elks Scholarship Award 1972
Join now to see all

Clinical Trials

Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer Start of enrollment: 1998 Aug 01
Completed
Phase 2
Combination Chemotherapy in Treating Women With Breast Cancer Start of enrollment: 1998 Aug 20
Completed
Phase 3
Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer Start of enrollment: 1999 Apr 01
Completed
Phase 2
Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Start of enrollment: 1999 Feb 01
Completed
Phase 2
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes Start of enrollment: 1999 Nov 16
Completed
Phase 3
Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer Start of enrollment: 2000 Nov 01
Completed
Phase 2
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer Start of enrollment: 2000 May 19
Completed
Phase 3
Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer Start of enrollment: 2001 Jan 01
Completed
Phase 3
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer Start of enrollment: 2000 Dec 04
Completed
Phase 3
Vinorelbine in Treating Older Women With Stage IV Breast Cancer Start of enrollment: 2001 Nov 01
Completed
Phase 2
Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer Start of enrollment: 2001 Jan 01
Unknown status
Phase 3
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2002 Jan 29
Completed
Phase 3
Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane Start of enrollment: 2003 Jun 01
Completed
Phase 2
Premenopausal Endocrine Responsive Chemotherapy Trial Start of enrollment: 2003 Aug 01
Terminated
Phase 3
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer Start of enrollment: 2004 May 01
Completed
Phase 2
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer Start of enrollment: 2004 Apr 01
Completed
Phase 2
Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2004 Dec 01
Completed
Phase 2
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2004 Aug 01
Completed
Phase 2
Sorafenib in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2004 Sep 01
Completed
Phase 2
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer Start of enrollment: 2004 Dec 01
Terminated
Phase 3
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer Start of enrollment: 2005 Jan 01
Completed
Phase 3
Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Start of enrollment: 2005 Aug 01
Completed
Phase 2
Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2006 Feb 01
Completed
Phase 2
Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2006 Feb 01
Completed
Phase 2
Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer Start of enrollment: 2005 Jul 01
Completed
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07
Active, not recruiting
Phase 3
VEGF Trap in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2007 Jan 01
Completed
Phase 2
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery Start of enrollment: 2007 Mar 16
Completed
Phase 2
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer Start of enrollment: 2008 Aug 28
Completed
Early Phase 1
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer Start of enrollment: 2009 Feb 01
Completed
Phase 2
Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831 Start of enrollment: 2000 May 01
Completed
Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer Start of enrollment: 2000 Oct 01
Completed
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2011 May 02
Active, not recruiting
Phase 1
OctavaPink for Women With Dense Breast After Negative Mammography Start of enrollment: 2014 Aug 01
Unknown status
Join now to see all

Publications & Presentations

PubMed

Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival.
Marla Lipsyc-Sharf, Karla V Ballman, Jordan D Campbell, Hyman B Muss, Edith A Perez, Lawrence N Shulman, Lisa A Carey, Ann H Partridge, Erica T Warner> ;JAMA Network Open. 2023 Oct 2
5 citations
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.
Jodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, Yaohua Ma, Xue Wang, David Zahrieh, David W Hillman, Kathleen S Tenner, Jennifer M Kachergus, Heather Ann Brauer, ...> ;Nature Communications. 2023 Apr 18
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial.
Pooja P Advani, Kathryn J Ruddy, Joerg Herrmann, Jordan C Ray, Emily C Craver, Greg Yothers, Reena S Cecchini, Corey Lipchik, Huichen Feng, Priya Rastogi, Eleftherios ...> ;Frontiers in Oncology. 2023 Jan 1
3 citations
Understanding Modern Medical Centers: Beyond Simone-Intersectional Maxims for a New Era.
Stephanie L Graff, Tanya Wildes, Narjust Duma, Don S Dizon, Noelle K LoConte, Edith Mitchell, Martina C Murphy, Edith A Perez, Sarah M Temkin, Pamela L Kunz, Karen M W...> ;Journal of Clinical Oncology. 2023 Mar 1
6 citations
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
Edith A Perez, Chau Dang, Caleb Lee, Jasmeet Singh, Kongming Wang, J Bradley Layton, Alicia Gilsenan, Michelle D Hackshaw, Javier Cortes> ;Breast Cancer Research and Treatment. 2022 Jul 1
4 citations
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials.
Saranya Chumsri, Zhuo Li, Daniel J Serie, Nadine Norton, Afshin Mashadi-Hossein, Kathleen Tenner, Heather Ann Brauer, Sarah Warren, Patrick Danaher, Gerardo Colon-Oter...> ;NPJ Breast Cancer. 2022 May 24
Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance).
Kostandinos Sideras, David W Hillman, Karthik Giridhar, Brenda F Ginos, Richard C Tenglin, Heshan Liu, Beiyun Chen, Winston Tan, Gerald G Gross, Rex B Mowat, Amylou C ...> ;The Oncologist. 2022 Apr 21
1 citations
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
Patricia A Ganz, Hanna Bandos, Charles E Geyer Jr, André Robidoux, Alexander H G Paterson, Jonathan Polikoff, Luis Baez-Diaz, Adam M Brufsky, Louis Fehrenbacher, Ann W...> ;Breast Cancer Research and Treatment. 2022 Feb 1
6 citations
Advancing Inclusive Research: Establishing Collaborative Strategies to Improve Diversity in Clinical Trials.
Owen Garrick, Ruben Mesa, Andrea Ferris, Edward S Kim, Edith Mitchell, Otis W Brawley, John Carpten, Keith D Carter, Joseph Coney, Robert Winn, Stephanie Monroe, Fabia...> ;Ethnicity & Disease. 2022 Jan 20
2 citations
Beta-2 adrenergic receptor gene (ADRB2) expression in HER2-positive early-stage breast cancer patients: a post-hoc analysis of the NCCTG-N9831 (Alliance) trial
Rafael Caparica, Yaohua Ma, Claudia De Angelis, Francois Richard, Christine Desmedt, Ahmad Awada, Martine Piccart, Edith A. Perez, Alvaro Moreno-Aspitia, Sunil Badve, ...> ;Clinical Breast Cancer. 2021 Dec 2
264 citations
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kevin Kalinsky, William E. Barlow, Julie R. Gralow, Funda Meric-Bernstam, Kathy S. Albain, Daniel F. Hayes, Nan Lin, Edith A. Perez, Lori J. Goldstein, Stephen Chia, S...> ;The New England Journal of Medicine. 2021 Dec 1
92 citations
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
Khalid El Bairi, Harry R Haynes, Elizabeth F Blackley, Susan Fineberg, Jeffrey Shear, Sophia Turner, Juliana Ribeiro de Freitas, Daniel Sur, Luis Claudio Amendola, Mas...> ;NPJ Breast Cancer. 2021 Dec 1
2 citations
Analysis of population differences in digital conversations about cancer clinical trials: Advanced data mining and extraction study
Edith A. Perez, Elizabeth M. Jaffee, John Whyte, Cheryl A Boyce, John D. Carpten, Guillermina Lozano, Raymond M Williams, Karen M. Winkfield, David I. Bernstein, Sung ...> ;JMIR Cancer. 2021 Sep 23
2 citations
Identification of the SARS-CoV-2 Entry Receptor ACE2 as a Direct Target for Transcriptional Repression by Miz1.
Jing Yang, Edith A. Perez, Changchun Hou, Pin Zhang, Michelle Van Scoyk, Robert A. Winn, Lijun Rong, Jing Liu> ;Frontiers in Immunology. 2021 Jul 7
12 citations
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge.
Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Z. Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Unt...> ;Cancer Treatment Reviews. 2021 May 20
10 citations
Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer
Hesham Elghazaly, Hope S. Rugo, Hamdy A. Azim, Sandra M. Swain, Banu Arun, Matti Aapro, Edith A. Perez, Benjamin O. Anderson, Frédérique Penault-Llorca, Pierfranco Con...> ;Cancers. 2021 May 8
6 citations
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated ...
Tufia C. Haddad, Jun He, Ciara C. O’Sullivan, Beiyun Chen, Donald W. Northfelt, Amylou C. Dueck, Karla V. Ballman, Kathleen S. Tenner, Hannah M. Linden, Joseph A. Spar...> ;Breast Cancer Research and Treatment. 2021 Apr 14
1 citations
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study.
Carlos Vargas, C.S. Thorpe, Amylou C. Dueck, Kathleen S. Tenner, Nancy E. Davidson, Silvana Martino, Thomas M. Pisansky, E. Shelley Hwang, Michele Y. Halyard, Barbara ...> ;Cancer. 2020 Dec 15
16 citations
Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases.
Kurt A. Jaeckle, Jesse G. Dixon, Stephen Keith Anderson, Alvaro Moreno-Aspitia, Gerardo Colon-Otero, Kathy Hebenstreit, Tejal Patel, Samarth L. Reddy, Edith A. Perez> ;Cancer Medicine. 2020 Sep 3
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-...
Roberto A. Leon-Ferre, Edith A. Perez, David W. Hillman, Celyne Bueno, Alejandra T. Perez, Beiyun Chen, Robert B. Jenkins, Donald W. Northfelt, David B. Johnson, Rober...> ;Breast Cancer Research and Treatment. 2020 Aug 1
26 citations
Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients.
Nadine Norton, Bahaaeldin Youssef, David W Hillman, Aziza Nassar, Xochiquetzal J Geiger, Brian M Necela, Heshan Liu, Kathryn J Ruddy, Mei-Yin C Polley, James N Ingle, ...> ;NPJ Breast Cancer. 2020 Jan 1
62 citations
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final res...
Edith A. Perez, Carlos H. Barrios, Wolfgang Eiermann, Masakazu Toi, Young-Hyuck Im, Pierfranco Conte, Miguel Martín, Tadeusz Pienkowski, Xavier Pivot, Howard A. Burris...> ;Cancer. 2019 Nov 15
46 citations
Incidence of late relapses in patients with HER2-positive breast cancer receiving adjuvant Trastuzumab: Combined analysis of NCCTG N9831 (alliance) and NRG oncology/NS...
Saranya Chumsri, Zhuo Li, Daniel J. Serie, Afshin Mashadi-Hossein, Gerardo Colon-Otero, Nan Song, Katherine L. Pogue-Geile, Patrick G. Gavin, Soonmyung Paik, Alvaro Mo...> ;Journal of Clinical Oncology. 2019 Oct 17
41 citations
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
Hyman B. Muss, Mei Yin C. Polley, Donald A. Berry, Heshan Liu, C. Cirrincione, Maria Theodoulou, Ann M. Mauer, Alice B. Kornblith, Ann H. Partridge, Lynn G. Dressler, ...> ;Journal of Clinical Oncology. 2019 Jul 24
3 citations
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane i...
Edith A. Perez, Sanne de Haas, Wolfgang Eiermann, Carlos H. Barrios, Masakazu Toi, Young-Hyuck Im, Pierfranco Conte, Miguel Martin, Tadeusz Pienkowski, Xavier Pivot, H...> ;BMC Cancer. 2019 Jun 24
Join now to see all

Journal Articles

Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer
Northfelt DW, Allred JB, Liu HS, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA, Am J Clin Oncol, 4/1/2014
International study on inter-reader variability for circulating tumor cells in breast cancer
Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothe F, Metallo J, Rouas G, Payne RE, Coombes RC, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavro..., Breast Cancer Res, 1/1/2014
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA , Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr,..., N Engl J Med, 1/1/2014
Clinical Roundtable MonographNew Developments in Metastatic Breast Cancer:Integrating Recent Data into Clinical Practice
Perez EA, Rugo HS, Vahdat LT, Clin Adv Hematol Oncol, 10/1/2013
How I Treat Patients with Advanced HER2-Positive Breast Cancer
Perez EA, How I Treat Patients with Advanced HER2-Positive Breast Cancer., 5/27/2013
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer
Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE, Sparano JA, J Clin Oncol, 7/1/2012
Re: predictability of adjuvant trastuzumab benefit in n9831 patients using the ASCO/CAP HER2-positivity criteria response
Perez EA, Dueck AC, J Natl Cancer Inst, 6/1/2012
Response Re: Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria
Perez EA, Dueck AC, J Natl Cancer Inst, 5/1/2012
Commentary
Perez EA, Serene M, Frances C, Clin Adv Hematol Oncol, 1/1/2012
Impact of race pace on development of hyponatremia in full- and half-marathoners
Maynard JR, Taylor WC III, McNeil RB, Shapiro SA, Mohseni MM, Vadeboncoeur TF, Silvers SM, Sumrall SV, Perez EA, Diehl NN, Impact of race pace on development of hyponatremia in full- and half-marathoners., 1/1/2012
Reply to S Mahesh
Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA, J Clin Oncol, 1/1/2012
Cardiotoxicity of Trastuzumab
Perez EA, Morgan JP, UpToDate, 1/1/2012
Baselga J Pertuzumab improved PFS when given with trastuzumab, chemotherapy [Perspective editorial]
Perez EA, HemOnc TODAY, 12/1/2011
New treatment strategies in the management of breast cancer
Perez EA, Eur J Cancer, 9/1/2011
Clinical Roundtable Monograph: Recent Advances in the Treatment of Breast Cancer: Highlights From the 2010 San Antonio Breast Cancer Symposium
Perez EA, Burstein HJ, Hudis C, Clin Adv Hematol Oncol, 1/1/2011
Evolving Paradigms for Optimizing Management of Breast CancerSymposium Report
Perez EA, Clinical Advances in Hematology and Oncology, 1/1/2011
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer
Swain SM, Jeong JH, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land..., Obstet Gynecol Surv, 11/1/2010
Compressing the timeline for cancer clinical trial activation
Doroshow JH, Hortobagyi G, Operational Efficiency Working Group of the Clinical Trials (Perez EA), Translational Research Advisory Committee, Natl Cancer Inst, 1/1/2010
What Your Patients Are Reading
Perez EA, The ASCO Post, 1/1/2010
Impact on cardiac toxicity with trastuzumab and radiotherapy: the question is still ongoing Reply to N Magne et al
Halyard MY, Pisansky TM, Dueck AC, Suman VJ, Pierce LJ, Solin LJ, Marks LB, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil S, Perez EA, J Clin Oncol, 12/1/2009
Reply to N Magne et Al
Halyard MY, Pisansky TM, Dueck AC, Suman VJ, Pierce LJ, Solin LJ, Marks LB, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil S, Perez EA, J Clin Oncol, 12/1/2009
The Role of Targeted Therapy in Breast Cancer Treatment
Patel TJ, Perez EA, Coping, 9/1/2009
HER2 Status Assessment: An Oncologist's Perspecitve
Perez EA, ASCO News & Forum, 4/1/2009
A Practical Clinical Approach to Adjuvant Therapy in Breast Cancer - An Update
Hines SL, Tan WW, Moreno-Aspitia A, Roy V, Vallow LA, McLaughlin SA, Perez EA, US Oncol, 4/1/2009
Reply to JM Guinebretiere and L Arnould et al
Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu M-Lm, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA, J Clin Oncol, 1/1/2009
Join now to see all

Books/Book Chapters

Expert Clinical Perspective: Controversies and Uncertainties in Diagnosis & Management of Cancer.
Chapter: Prevention and adjuvant therapy in breast cancer.
Page 523 - 531Gardner FP, Perez EAEditors: S. Abutalib.Wiley-Blackwell Health Sciences2014
The CTSA Program at NIH: Opportunities for Advancing Clinical and Translational Research
Leshner AI, Terry SF, Axelrod S, Bond EA, Bonham AC, Curry SJ, Dennery PA, Horwitz RI, Kahn JP, Kelley RT, McCabe M, Perez EA, Rosen CJ.Editors: Leshner AI, Terry SF, Schultz AM, Liverman CT.The National Academies Press, Washington, DC2013
Management of breast diseases.
Chapter: Metastatic breast cancer.
Page 425 - 449Patel TA, Perez EAEditors: Jatoi I; Kaufmann M.Springer, Heidelberg; New York2010
Diseases of the breast.
Chapter: Side effects of systemic therapy: neurocognitive, cardiac, and secondary malignancies.
Page 692 - 704Moreno Aspitia A, Perez EAEditors: Harris JR; et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PAEdition 4th,2010
A National Cancer Clinical Trials System for the 21st Century
Mendelsohn J, Moses HL, Arbuck S, Berry D, Carducci MA, Dilts DM, Ellenberg SS, Fyfe G, Grubbs SS, Hricak H, Kaplan R, Liu MC, Newcomer LN, Perez EA, Sawyers CL, Schil...The National Academies Press, Washington, DC2010
Principles and Practice of Surgical Oncology.
Chapter: Adjuvant Therapy in Breast Cancer.
Charles AJ, Roy V, Perez EA2009
Diseases of the Breast
Chapter: Side Effects of Systemic Therapy: Neurocognitive, Cardiac, and Secondary Malignancies.
Page 692 - 704Moreno-Aspitia A, Perez EAEditors: Jay R. Harris, M.D.; Marc E. Lippman, M.D.; Monica Morrow, M.D.; C. Kent Osborne, M.D..Lippincott Williams & Willkins, Philadelphia, PAEdition 4th,2009
Pharmacology and therapeutics: principles to practice.
Chapter: Breast cancer.
Page 933 - 944Roy V, Perez EAEditors: Waldman SA, Terzic A.Saunders/Elsevier, Philadelphia, PA2009
Handbook of therapeutic antibodies. Volume 3.
Chapter: Bevacizumab (Avastin).
Page 779 - 812Diaz-Rubio E, Perez EA, Giaccone G2008
2007 Educational Book of the American Society of Clinical Oncology.
Chapter: Human Epidermal Growth Factor 2 - positive Breast Cancer: Treatment of Metastatic Disease - from Bench to Bedside.
Page 90 - 94Amar S, Perez EA2007
Breast cancer: Translational therapeutic strategies.
Chapter: HER2-Positive Breast Cancer: Current Treatment Strategies.
Page 189 - 202Perez EA, Baweja MEditors: Gary H. Lyman & Harold J. Burstein.Taylor & Francis Publishing Company2007
Textbook of Breast Cancer: A Clinical Guide to Therapy
Chapter: Conventional adjuvant chemotherapy: Where are we 30 years later?
Page 225 - 239Perez EAEditors: Bondadonna G, Hortobagyi GN, Valagussa P.London & New York, London & New YorkEdition 3rd,2006
Breast cancer and molecular medicine.
Chapter: Molecular profiling in breast cancer.
Page 977 - 1006Perez EA, Enui AEEditors: Piccart MJ, et al.Springer, Berlin2006
ASCO 2005 Educational Book, 41st Annual Meeting Orlando, FL 2005.
Chapter: Aromatase inhibitors and bone health.
Page 27 - 34Mincey BA, Perez EA2005
Oncology news international cancer management: a multidisciplinary approach.
Chapter: Aromatase inhibitors as adjuvant therapy for breast cancer.
Page 31 - 54Perez EASt. Louis, MO2005
American Society of Clinical Oncology. American Society of Clinical Oncology 2004 Educational Book.
Chapter: Beyond chemotherapy: incorporation of targeted agents for adjuvant treatment of breast cancer.
Page 23 - 27Perez EAASCO, Alexandria, VA2004
Manual of Breast Diseases.
Chapter: Metastatic breast cancer.
Page 365 - 387Perez EA, Russell CAEditors: Jatoi I.Lippincott Williams & Willkins, Philadelphia, PA2002
(TeleLecture: Clinics in Oncology). J of Oncology: Index & Reviews.
Chapter: Role of Trastuzumab in breast cancer.
Page 10 - 12Perez EA2000
Mit Taxol in der Therapie solider Tumeron ins nachste Jahrtausend.
Chapter: Antiemetic therapy with granisetron with and without corticosteroids and NK-1 inhibitors.
Page 156 - 161Perez EAAktuelle Onkologie1999
Conn's current therapy 1997.
Chapter: Nausea and vomiting.
Page 4 - 9Perez EA, Hallstone AEEditors: Nausea and vomiting..W. B. Saunders Company, Philadelphia, PA1997
Supportive care of the cancer patient.
Chapter: Improved control of chemotherapy-induced emesis.
Page 121 - 139Perez EAEditors: Sweetenham JW, Williams C.Arnold, London1997
Chapter: Taxol (paclitaxel) injection and doxorubicin combination chemotherapy: considerations regarding cardiotoxicity issues.
Perez EABristol-Myers Squibb Company, Princeton, NJ1997
Cecil textbook of medicine.
Chapter: Molecular mechanisms of drug resistance.
Page 1056 - 1060DeGregorio MW, Perez EAEditors: Bennett JC, Plum F.W. B. Saunders Company, Philadelphia, PAEdition 20th,1996
Mediguide in oncology.
Chapter: Prevention and control of chemotherapy induced emesis in the 1990s.
Page 1 - 8Perez EA1994
Satellite Symposium. European Society of Medical Oncology (ESMO)
Chapter: Acute emesis: can oral treatment match IV?
Page 18 - 25Perez EA1994
Join now to see all

Abstracts/Posters

Targeting hsp90 in breast cancer: ENCHANT-1 (nct01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic HER2-positive o...
Cameron D, Spector N, Gomez H, Hickish T, Vandat L, Kim SB, Sheldon E, El-Hariry I, Perez EA, Awada A, Eur J Cancer, 3/1/2014
Interim safety of pertuzumab in combination with trastuzumab and vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic bre...
Perez EA, Lopez-Vega JM, Petit T, Zamagni C, Freudensprung U, Bastiere-Truchot L, Walker R, Andersson M, Eur J Cancer, 3/1/2014
Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Adams S, Gray R, Demaria S, Goldstein LJ, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW, Sparano JA, Badve SS, Cancer Res, 12/1/2013
A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): Effect of post-progression anti-cancer...
Awada A, Kaufman PA, Yelle L, Cortes J, Wanders J, O’Shaughnessy J, Olivo MS, He Y, Garzon F, Dutcus CE, Binder TA, Twelves C, Perez EA, Cancer Res, 12/1/2013
The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 ...
Awada A, Spector N, El-Hariry I, Rodriguez AA, Erban JK, Cortes J, Gomez H, Kong A, Hickish T, Fein L, Vahdat L, MacPherson I, Canon J-L, Mansoor S, Giovanne A, McAdam..., Cancer Res, 12/1/2013
Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301.
Kaufman PA, Yelle L, Cortes J, Perez EA, Awada A, Wanders J, Olivo MS, He Y, Dutcus CE, Twelves C, Cancer Res, 12/1/2013
The prognosis of small HER2+ breast cancers: A meta-analysis of the randomized trastuzumab trials.
O’Sullivan CC, Holmes E, Spielman M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, de Azambuja E, Piccart-Gebhart M, Zujewski JA, ..., Cancer Res, 12/1/2013
Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer.
Perez EA, Lopez-Vega JM, Del Mastro L, Petit T, Zamagni C, Freudensprung U, Bastiere-Truchot L, Walker R, Andersson M, Cancer Res, 12/1/2013
EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial.
Rimm DL, Holmes E, Schalper K, Bradbury I, Zarrella E, Ellis C, Baselga J, Eidtmann H, Piccart M, Harbeck N, Pusztai L, Perez EA, Cancer Res, 12/1/2013
Limits of [18F]-FLT PET as a clinical biomarker of proliferation in breast cancer.
Schmidt EV, Blackman S, Iannone R, Senderak ET, Railkar RA, Evelhoch PD, Mozley PD, Perez EA, McDonough M, Rimawi M, Tolaney S, Kim S-B, Chung H-C, Cancer Res, 12/1/2013
Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribuli...
Cortes J, Awada A, Kaufmann PA, Yelle L, Perez EA, Velikova G, Wanders J, Olivo M, He Y, Ductus C, Simons R, Bischoff J, Twelves C, Onkologie, 10/1/2013
A phase Ill, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treat...
Kaufmann PA, Cortes J, Awada A, Yelle L, Perez EA, Wanders J, Olivo M, He Y, Ductus C, Bischoff J, Twelves C, Onkologie, 10/1/2013
New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with mbc treated with eribulin or capecitabine in ...
Perez EA, O'Shaughnessy J, Twelves C, Cortes J, Awada A, Yelle L, Wanders J, Olivo M, He Y, Kaufman PA, Eur J Cancer, 9/1/2013
Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): results from an expanded access study.
Yardley DA, Krop IE, LoRusso P, Robert NJ, Mayer M, Abidoye OO, Lai C, Yoo B, Perez EA, J Clin Oncol, 9/1/2013
The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2...
Awada A, Rodriguez AA, Kong A, Erban JK, Cortes J, Mano MS, Perez EA, El Hariry I, Vukovic VM, Teofilovici F, Yalcin I, Bradley R, Cameron DA, J Clin Oncol, 5/1/2013
Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studie...
Clynes R, Knutson KL, Ballman KV, Erskine CL, Norton N, Sumrall SV, Northfelt DW, Tan W, Calfa CJ, Pegram MD, Perez EA, J Clin Oncol, 5/1/2013
Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribuli...
Cortes J, Awada A, Kaufman PA, Yelle L, Perez EA, Velikova G, Wanders J, Olivo MS, He Y, Dutcus C, Simons WR, Twelves C, J Clin Oncol, 5/1/2013
Crozier JA, Necela BM, Thompson EA, Geiger X, Moreno-Aspitia A, McCullough AE, Pockaj BA, Cunliffe H, Sun Z, Kalari KR, Kachergus JM, O'Shannessy DJ, Maltzman JD, Ball..., J Clin Oncol, 5/1/2013
Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patie...
Hoch U, Fry DG, Chia YL, Caygill K, Hannah AL, Perez EA, Cortes J, Awada A, O'Shaughnessy J, Twelves C, Rugo HS, Im SA, Xu B, Anderes KL, Davis DW, J Clin Oncol, 5/1/2013
A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treat...
Kaufman PA, Cortes J, Awada A, Yelle L, Perez EA, Wanders J, Olivo MS, He Y, Dutcus C, Twelves C, J Clin Oncol, 5/1/2013
Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study...
Knutson KL, Perez EA, Ballman KV, Erskine CL, Fox N, McCarl CA, Norton N, Sumrall SV, Northfelt DW, Tan W, Calfa CJ, Pegram MD, Clynes R, J Clin Oncol, 5/1/2013
Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple-negative b...
Moreno-Aspitia A, Liu H, Hillman DW, Rowland KM, Geiger X, Stella PJ, Kourlas P, Gross HM, Karlin NJ, Bury MJ, Soori GS, Nassar A, Perez EA, Alliance for. N0937 (Allia..., J Clin Oncol, 5/1/2013
The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831.
Perez EA, Butler SM, Dueck AC, Baehner FL, Jamshidian F, Cherbavaz DB, Thompson EA, Shak S, Kaufman PA, Davidson NE, Gralow J, Asmann YW, Ballman KV, J Clin Oncol, 5/1/2013
Biomarker testing methods in breast, gastric, and lung cancers: A benchmarking survey of NCI cancer centers.
Schink JC, Trosman JR, Weldon CB, Siziopikou KP, Gradishar WJ, Tsongalis GJ, Patel JD, Benson AB, Perez EA, J Clin Oncol, 5/1/2013
Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes:...
Shulman LN, Berry D, Cirrincione CT, Becker H, Perez EA, O'Regan R, Martino S, Shapiro CL, Atkins J, Schneider C, Kimmick GG, Burstein HJ, Norton L, Muss HB, Hudis C, ..., J Clin Oncol, 5/1/2013
Join now to see all

Lectures

Updates on Metastatic Breast Cancer: HER2+
Amelia Island, FL - 1/1/2014
Breast Cancer: New Advances in Breast Cancer Management
Wichita, KS - 1/1/2014
State of the Art Anti-HER2 Therapies for Breast Cancer
Dublin, Ireland - 1/1/2014
Gene Profiling for Early Stage Breast Cancer: What is Clinically Relevant?
Kona, HI - 1/1/2014
Sixteen years of Targeted HER2+ Therapy in Breast Cancer
London, United Kingdom - 1/1/2014
Neoadjuvant and Adjuvant Hormonal Manipulation in Early Stage Breast Cancer
New Orleans, LA - 1/1/2014
Metastatic Breast Cancer: Now and the Future
Paris, France - 1/1/2014
Advances in Management of Metastatic HER2+ BC
Amelia Island, FL - 1/1/2013
The Conquest of Cancer and the Next Generation of Cancer Researchers
Washington, DC - 1/1/2013
Approach to HER2+ Mets Breast Cancer: the Newest and Greatest and the Real World
Kuala Lumpur, Malaysia - 1/1/2013
Breast Cancer Treatment-State of the Art Now and for the Future: What is the Next Best Thing?
Kuala Lumpur, Malaysia - 1/1/2013
Opportunities and Barriers to Personalized Medicine
Kuala Lumpur, Malaysia - 1/1/2013
New Treatments in Breast Cancer
Paris, France - 1/1/2013
Personalized Medicine in Breast Cancer
Paris, France - 1/1/2013
Individualized Management of Breast Cancer: A Post San Antonio Meeting Update
Mayo School of Continuous Professional Development, Jacksonville, Florida - 2/11/2012
Impact of Adjuvant Trastuzumab on Local Regional Recurrence: Data from the NCCTG N9831 Study.
San Antonio, TX - 1/1/2012
Molecular Diagnosis - the US Experience
Sao Paulo, Brazil - 1/1/2012
Generally Accepted Standards for Clinical Trial Approval
Sao Paulo, Brazil - 1/1/2012
International Considerations for Multi-site Trials
Sao Paulo, Brazil - 1/1/2012
International Insurance Requirements for Patients
Sao Paulo, Brazil - 1/1/2012
Safety and Surveillance Reporting for Adverse Events, Coding, etc.
Sao Paulo, Brazil - 1/1/2012
New Updates on Adjuvant Chemotherapy in Breast Cancer
Shanghai, China - 1/1/2012
Comparison of fusion detection in RNA-SEQ and Mate-Pair DNA Seq Data.
Marco Island, FL - 1/1/2012
Adjuvant Treatment: Chemotherapy or not Chemotherapy in Node Positive Hormonal Responsive Breast Cancer Patients: the Current Dualism Lecture
Rome, Italy - 1/1/2011
Integration of Molecular Profiling with Clinical Practice Lecture
Rome, Italy - 1/1/2011
Join now to see all

Other

ALTTO Trials Findings For Treating HER2+ Breast Cancer - Mayo Clinic.
Perez EA, Mayo Clinic
6/1/2014
Dr. Perez on a Genomic Analysis of the NCCTG N9831 Adjuvant Trastuzumab Trial.
Perez EA, OncLive
6/1/2014
The Race Against Breast Cancer: What Mayo Clinic Has Learned So Far.
Perez EA, Thompson EA, Mayo Clinic
2/1/2014
Metastatic Breast Cancer Treatment Challenges.
Brufsky AM, Hurvitz S, O'Shaughnessy J, Perez EA, Rugo HS, Seidman AD, OncLive Peer Exchange
6/1/2013
Edith A. Perez, MD: Anti-HER2 Therapies.
Perez EA, The Group Room
3/1/2013
Dr. Perez on the Antibody-Drug Conjugate T-DM1.
Perez EA, OncLive
2/1/2013
Dr. Edith Perez on Study 301 That Compared Eribulin to Capecitabine in MBC.
Perez EA, Targeted Oncology
2/1/2013
Dr. Perez on the Adjuvant Treatment of Breast Cancer.
Perez EA, OncLive
1/1/2013
Dr. Perez on the Phase III Eribulin/Capecitabine Study.
Perez EA, OncLive
1/1/2013
Dr. Edith Perez Discusses Anti-HER2 Therapies - 2012 SABCS.
Perez EA, Breast Cancer Answers
12/1/2012
Dr. Perez on Patient Selection for Adjuvant Chemotherapy.
Perez EA, OncLive
3/1/2012
Dr. Perez Describes Retesting Recurrent Breast Cancer.
Perez EA, OncLive
2/1/2012
Dr. Perez Discusses Optimizing Adjuvant Therapy.
Perez EA, OncLive
2/1/2012
Dr.Perez Discusses Obesity as a Predictive Marker.
Perez EA, OncLive
1/1/2012
Dr. Perez Discusses the B-34 Clodronate Study.
Perez EA, OncLive
12/1/2011
Dr. Perez Discusses the BOLERO-2 Everolimus Trial.
Perez EA, OncLive
12/1/2011
Dr. Edith Perez Discusses Her Ongoing Research.
Perez EA, OncLive
4/1/2011
Dr. Perez on her Anticipated Results for ASCO and SABCS.
Perez EA, OncLive
1/1/2011
2010 SABCS Interview with Edith A. Perez, M.D.
Perez EA, American Association for Cancer Research
12/1/2010
Adjuvant treatment options for early stage HER2-positive breast cancer: Where are we now?
Perez EA, PeerView in Review
1/1/2006
Weekly paclitaxel, carboplatin, and trastuzumab shows better efficacy and lower toxicity for the treatment of HER2-positive metastatic breast cancer compared with dosi...
Perez EA, PeerView in Session direct from 26th San Antonio Breast Cancer Symposium (SABCS)
1/1/2003
Audioforum on chemotherapy-induced nausea and vomiting.
Perez EA, Scientific Exchange Inc, Greenwich, CT
1/1/1997
Screening for breast cancer: methods and controversies.
Perez EA, PrimePractice
1/1/1996
Tamoxifen and endometrial cancer: making sense of the studies.
Perez EA, PrimePractice
1/1/1996
Cardiotoxicity of trastuzumab
Perez EA, Morgan JP
http://www.uptodate.com/contents/cardiotoxicity-of-trastuzumab
UpToDate, Wolters Kluwer Health - 2013-02-11
Join now to see all

Press Mentions

Lack of Diversity in Clinical Trials Costs Billions of Dollars. Incentives Can Spur InnovationAugust 3rd, 2022
Starting the Conversation: Panel Discusses National Black Family Cancer Awareness WeekJune 17th, 2022
Artiva Biotherapeutics Appoints Edith a. Perez, M.D., to Its Board of Directors and Clinical Advisory BoardMay 5th, 2022
Join now to see all

Grant Support

Role Of Immunity In Efficacy Of Chemotherapy PLUS TrastuzumabNational Cancer Institute2011–2012
Predictive Biomarkers Of Adjuvant Trastuzumab In The Her2+N9831 Intergroup TrialNational Cancer Institute2008–2011
Breast CancerNational Cancer Institute2001–2002